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Abstract
Background: Giant cell arteritis is a vasculitis of large and middle-sized arteries that affects patients aged over 50 years.
It can show a typical clinical picture consisting of cranial manifestations but sometimes nonspecific symptoms and
large-vessel involvement prevail. Prompt diagnosis and treatment is essential to avoid irreversible damage.
Discussion: There has been an increasing knowledge on the occurrence of the disease without the typical cranial
symptoms and its close relationship and overlap with polymyalgia rheumatica, and this may contribute to reduce the
number of underdiagnosed patients. Although temporal artery biopsy is still the gold-standard and temporal artery
ultrasonography is being widely used, newer imaging techniques (FDG-PET/TAC, MRI, CT) can be of valuable help to
identify giant cell arteritis, in particular in those cases with a predominance of extracranial large-vessel manifestations.
Conclusions: Giant cell arteritis is a more heterogeneous condition than previously thought. Awareness of all the
potential clinical manifestations and judicious use of diagnostic tests may be an aid to avoid delayed detection and
consequently ominous complications.
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Background
Giant cell arteritis (GCA) is a non-necrotizing granuloma-
tous vasculitis affecting large and middle-sized arteries.
Histologic changes, mainly inflammatory infiltrates with
the presence of multinucleated giant cells between the
media and intima layers and disruption of the internal
elastic lamina, ultimately leads to partial or complete
obstruction of local arterial blood flow with the corre-
sponding clinical manifestations of ischemia [1–6].
Branches of the aortic arch are most often affected. How-
ever, non-specific clinical features related to the general
inflammatory state, such as low-grade fever, malaise,
fatigue, constitutional symptoms or anemia, may prevail
in some cases. In this later group of patients, a lower index
of suspicion may yield a significant diagnostic and thera-
peutic delay with potential serious consequences [7]. In
addition, involvement of the aorta is associated with a
higher risk for developing aneurysms and dissection over
the course of the disease, especially in the thoracic
segment [8–10].
Most common local symptoms include acute head-
ache, scalp pain, jaw, tongue or limb claudication, and
visual deficits. Clinical features of polymyalgia rheuma-
tica (PMR) may be present before, simultaneously or
after diagnosis of GCA has been established [11, 12].
Other findings may occur in a minor proportion, includ-
ing peripheral neuropathy, dry cough, sore throat or
stroke [13]. It is remarkable that strokes affect more
often the vertebrobasilar territory at early stages and the
carotid branches during follow-up [14, 15]. In rare cases,
complete arterial occlusion can end in infarction of
distal territories such as the scalp, tongue or limbs.
Ocular involvement may lead to irreversible visual
loss, one of the most feared complications, and, for this
reason, early diagnosis and treatment of GCA is of
major importance. It usually presents as an anterior
optic ischemic neuropathy or less commonly as retinal
artery occlusion. In addition, visual impairment can be
the result of stroke affecting the vertebra-basilar terri-
tory [16]. Previous episodes of amaurosis fugax have
been associated with an increased risk for permanent
visual loss [16]. Other ocular manifestations such as
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episcleritis, scleritis or extraocular muscle palsies are less
commonly reported [17–19].
On physical examination, it is important to look for
abnormalities in temporal arteries (i.e. thickening, ten-
derness, beading or reduced pulsation) [20, 21], but
attention must also be focused on the remaining periph-
eral arterial territories to disclose pulse deficits, bruits or
asymmetric arterial pressure measurements in any of the
four limbs [22]. Although there is no specific laboratory
marker for the disease, acute phase reactants (platelets,
erythrocyte sedimentation rate and/or C reactive
protein) are elevated in the majority of patients [23].
Conversely, normal values are not sufficient to rule out
the diagnosis when there is a strong clinical suspicion.
Anemia can also be present, as well as raised liver
enzymes [2, 13, 23].
Temporal artery biopsy, performed with appropriate
technique, is considered the gold-standard for diagnosis
[1]. Nevertheless, the most recent EULAR guidelines
consider that early imaging test, such as temporal artery
ultrasound, performed by a trained specialist using
appropriate operational procedures and settings, may be
an alternative to the temporal artery biopsy [24]. Treat-
ment should not be delayed due to pending biopsy
results, and it has been demonstrated that histologic
changes are recognizable within two weeks after starting
therapy [25, 26]. Advances in imaging over the last few
years have constituted a major step forward in the diag-
nosis of GCA. Besides the use of duplex ultrasonography
of the temporal artery for the diagnosis of GCA in
patients presenting with the typical pattern of cranial
manifestations, other Imaging techniques, such as mag-
netic resonance, computed tomography (CT)-angiog-
raphy, and [18F]-fluorodeoxyglucose (FDG)-positron
emission tomography (PET/CT) can help to diagnose
patients with predominant extracranial manifestations,
many of them presenting with atypical manifestations of
the disease [24]. These new imaging techniques allows
to identify clinically silent large vessel involvement [27].
Experts in the field consider that in some cases they may
also be used to monitor response to treatment.
Glucocorticoids are the cornerstone of treatment
[2–6]. Some adjuvant therapies, such as methotrexate,
have been used as glucocorticoid-sparing agents, thus
minimizing their adverse effects, with conflicting results
in terms of safety and clinical benefit [28]. It is also recom-
mended to use low-dose aspirin to reduce the risk of asso-
ciated cardiovascular events [20, 29, 30]. More recently,
open-label studies and clinical trials have shown that the
use tocilizumab, a novel humanized monoclonal antibody
against IL-6, yields significant efficacy in achievement of
sustained, corticosteroid-independent remissions [31, 32].
The aim of this report is to help physicians to early
recognize symptoms of GCA, with special emphasis on
those patients with atypical or extra-cranial manifesta-
tions (“occult” GCA), in order to perform an appro-




GCA is the most common type of vasculitis in Europe
and North America. It is a disease of the elderly, with a
peak of prevalence in the seventh and eighth decades of
life [33]. In fact, one of the most constant diagnostic cri-
teria has been an age over 50 years. With the progressive
expansion of life expectancy over the last decades and
the consequent aging of general population, along with
shortened periods from disease onset to final diagnosis,
the prevalence of GCA tends to increase gradually
despite steady incidence rates described in some studies.
GCA is usually more frequent in women, with an aver-
age ratio around 2:1, and more common in patients of
Scandinavian origin [3, 5, 13, 33]. A genetic predispos-
ition has been found, with special relevance of some
alleles of the HLA class II region, in particular those
with HLA-DRB*04 [34, 35].
The etiology is still unknown, but certain parallelism
of peak incidences with some infectious outbreaks and
detection of viral molecules in biopsy specimens have
tempted some investigators to hypothesize than an in-
fection might at least trigger the inflammatory reaction.
However, the exact pathogenic explanation of this find-
ing, if any, remains to be elucidated. Microorganisms
that have been implicated include varicella zoster virus,
Mycoplasma pneumoniae, Chlamydia pneumoniae, and
parvovirus B19 [36–38], but infectious agents have not
been definitely proven to play a major causal role nor be
the sole immunologic trigger [39].
Incidence of GCA was found to increase in some re-
gions [40], in other studies there was a trend towards
lower rates [41, 42], and others described stability [43].
Higher awareness of the disease by attending physicians
and underestimation of more atypical extra-cranial
forms in the past may have played a role in these
variations. Interestingly, probably because physicians
are more familiar with the disease, some series have
shown a decline of visual manifestations in recent
years [18, 40, 44].
GCA and PMR, two overlapping conditions
PMR is an inflammatory disorder that usually presents
as severe pain and stiffness of shoulders and proximal
arms. Involvement of other regions, mainly the neck,
pelvic girdle and thighs, can also occur. Raised labora-
tory inflammatory markers are generally observed.
Ultrasonographic findings (characteristic bursitis and
tenosynovitis) have been added to the latest ACR and
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EULAR preliminary classification criteria [45]. PMR usu-
ally has a good and rapid response to glucocorticoid
therapy at lower doses than those required for treating
GCA [12].
GCA shares epidemiological, physiopathological and
clinical features with PMR, and they often overlap in a
synchronic or metachronic manner in the same patient
[11]. In fact, for some authors they comprise two
variants of a single disease. It is estimated that about
20% of patients with PMR have associated GCA [46, 47],
although this frequency was higher, up to 50%, in tem-
poral-artery-biopsy-proven cases [48]. Moreover, when
imaging techniques such as FDG-PET/CT are performed
in patients with PMR, they have shown that at least one
third of them may have large-vessel involvement that
may be clinically silent and without associated typical
cranial ischemic manifestations [12]. A recent study has
disclosed that large-vessel vasculitis involvement is often
observed in patients with persistent PMR who have in-
flammatory low back pain, predominant pelvic girdle
and or diffuse limb pain [49].
Therefore, it is advocated that patients with a newly
diagnosis of PMR should be screened for large-vessel
inflammation and concomitant GCA using clinical
predictors [49] and whenever confirmatory imaging
techniques were available. In addition, close observation
should be maintained over the entire course of the dis-
ease, since typical features of GCA and ischemic events
(including visual deficits) have been described during the
follow-up of patients with an initial diagnosis of isolated
PMR, thus requiring higher corticosteroid doses to avoid
irreversible damages [50, 51], especially blindness [52].
“Pure” (isolated) PMR patients tend to show lower
values of inflammatory parameters and milder degrees
of anemia and thrombocytosis compared to those with
PMR associated with clinical features of GCA [53]. Also,
patients with suspected PMR who do not have a good
response to low-dose glucocorticoids or show marked
systemic symptoms may actually represent a form of
extra-cranial GCA [12].
Cranial vs extra-cranial disease
In recent years there have been a growing interest and
knowledge on cases with involvement of extra-cranial
territories, in contrast to the “classic” cranial manifesta-
tions. Incidence of extra-cranial disease seems to have
been underestimated in the past. This was formerly sup-
ported by some post-mortem studies and histological
analysis of case series of vascular surgery of the aorta or
its main branches [54]. The widespread use of whole-
body imaging techniques (i.e. FDG-PET/CT and CT or
MRI angiography) and a greater awareness of the disease
in patients with atypical manifestations will probably
raise this incidence even more in the future.
Most patients with a recent diagnosis of temporal-ar-
tery-biopsy-proven GCA have no clinical evidence of
vascular ischemic manifestations [48, 55]. However, im-
aging techniques often show asymptomatic extra-cranial
vascular involvement in these patients and support the
claim that GCA involves arteries far beyond the tem-
poral and other cranial arteries [56, 57]. Moreover, the
risk of developing aortic aneurysm or dissection has
been estimated up to 17 times greater than in patients
without GCA, additionally increasing when other cardio-
vascular risk factors such as hypertension are present
[8, 10]. For these reasons, some authors advocate screen-
ing imaging of the aorta at the time of diagnosis and
during follow-up, since symptoms usually develop several
years later [10, 58]. The presence of cardiovascular risk
factors of atherosclerosis at the time of diagnosis of GCA
may influence the development of severe ischemic mani-
festations of the disease [59]. On the other hand, some
authors consider that GCA patients with a pattern of
extra-cranial vascular involvement, without the typical
cranial ischemic manifestations of the disease, have lower
risk of having ophthalmologic complications over the
course of the disease, but in turn they are more prone to
relapses and large-vessel complications [60, 61].
Isolated extra-cranial GCA represents a diagnostic
challenge since signs and symptoms may be nonspecific
(fever, fatigue, weight loss) unless local ischemic mani-
festations appear. A significant proportion of patients
with ischemic features attributed to atherosclerosis or
embolic origin could represent an extra-cranial form of
this vasculitis, particularly when cardiovascular risk
factors are scarce or absent. In addition, laboratory
inflammatory markers tend to be lower in this group of
patients [62]. This difficulty in diagnosis often leads to a
greater diagnostic delay compared with patients suffer-
ing typical cranial symptoms [7, 63]. Interestingly, pa-
tients with predominant large-vessel-vasculitis pattern
are younger and have more commonly PMR features
and longer duration of symptoms at GCA diagnosis than
those with predominant cranial manifestations [60, 61].
Moreover, the frequency of a positive temporal artery
biopsy in these is much lower than in those with the
classic pattern of GCA [60, 63]. Because of that, in these
patients the diagnosis must often be relied on large-ves-
sel inflammatory signs on imaging tests, as retrieval of
arterial specimens in other territories entails significant
morbidity.
Current diagnostic tools and diagnostic challenges
Although temporal artery biopsy is considered by many
clinicians as the gold-standard for the diagnosis of GCA
[1], focal or segmental inflammatory changes and tech-
nical pitfalls of the procedure make it difficult to
confirm this condition in a significant proportion of
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patients. Diagnostic yield of biopsy varies greatly depend-
ing on the length of the excised specimen and whether it
is performed unilaterally or bilaterally [64, 65]. The
traditional recommendation was to obtain an arterial sam-
ple of at least 2–3 cm of length, although more recent
studies consider that 1 cm could be enough for histologic
diagnosis.
Some authors have designed predictive models as an
aid to select those patients with higher probability of
having GCA, but it should be kept in mind that these
calculators do not take into account those cases of GCA
with a negative biopsy result [66].
Color duplex ultrasonography has been proposed as a
harmless, noninvasive and readily available alternative to
temporal artery biopsy for diagnostic purposes [3, 67].
With the demonstration of arterial wall edema (known
as the “halo sign”) it may reach a specificity above 90%
[3]. However, sensitivity tends to be lower, it is an oper-
ator-dependent technique, and specificity may be de-
creased in patients with atherosclerotic disease [68].
Ultrasonography must therefore be performed by
personnel with expertise in the field, in order to avoid
false positive and false negative results. Although it
could also be an aid to localize the most affected
temporal arterial segment for histologic assessment,
some studies have not shown superiority of this strategy
compared with non-US-guided biopsy [69].
Cranial arterial wall thickening can also be disclosed
by means of contrast-enhanced high-resolution MRI,
with sensitivities near 90%, but its usefulness decreases
when patients have received treatment for more than 5
days and it is a more expensive and less available tech-
nique [70–72]. With respect to this, the central bright
spot sign (optic nerve head enhancement on MRI) has
been proposed as a useful tool to distinguish acute stage
GCA from other nonarteritic anterior ischemic optic
neuropathies [73].
The use FDG-PET/CT in patients with suspected or
confirmed GCA has been progressively increasing in re-
cent years. It allows detection of large-vessel involve-
ment prior or after diagnosis has been made [3, 48, 74]
and has special value when there is suspicion of isolated
extra-cranial disease [58]. Nevertheless, it is an expen-
sive and not universally available technique and is
associated with radiation exposure. Moreover, its sensi-
tivity decreases in patients undergoing glucocorticoid
therapy. Some studies comparing FDG-PET/CT and CT-
angiography have shown similar sensitivities for both
modalities regarding disclosure of large-vessel inflamma-
tion, although the former seems to have a higher positive
predictive value [75–77]. A cutoff value of > 2.2 mm of
aortic wall thickening measured by CT scan has been
suggested for diagnostic purposes [78]. The remarkably
improved performance of all these imaging modalities
and their increasing availability are reflected in the re-
cently published EULAR recommendations, which
stated that temporal artery biopsy could be obviated in
patients with a strong clinical suspicion and a positive,
reliable imaging test [24].
In addition to imaging advances, measurement of
autoantibodies against ferritin has also been reported as
an alternative diagnostic laboratory biomarker, but its
usefulness has not been fully demonstrated yet, and it
seems far from everyday clinical practice [79, 80].
GCA is not always a readily suspected condition. Ini-
tial diagnosis often relies on primary care physicians and
specialists in Geriatrics, so they should be aware of the
importance of a prompt detection to avoid serious and
irreversible complications due to the delay in treatment.
As discussed before, a typical clinical picture is not
Table 1 “Red flags” on history or physical examination that may
suggest GCA
Typical cranial disease
New onset headache (mainly temporal)
Scalp pain
Jaw or tongue claudication
Acute visual deficits
Temporal artery abnormalities on physical examination
Anterior ischemic optic neuropathy or central retinal artery occlusion
on ophthalmologic examination
Associated constitutional symptoms
Associated polymyalgia rheumatica symptoms
Associated anemia an elevated C reactive protein/erythrocyte
sedimentation rate
Extra-cranial disease
Ischemic signs and symptoms of extremities, especially in the






Distal necrosis or gangrene






Polymyalgia rheumatica that relapses or responds poorly to standard
glucocorticoid therapy
Polymyalgia rheumatica with associated ischemic manifestations
Detection of aneurysm or dissection of aorta and main branches
along with raised inflammatory markers
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always present. On the other hand, healthy patients with
advanced age may have raised values of erythrocyte
sedimentation rate. A survey directed to general practi-
tioners in the UK disclosed that more than 20% of them
would rule out GCA if headache was not present among
the patient’s symptoms [81]. Other study showed that
mean delay from initial symptoms to final diagnosis of
GCA was 9 weeks, but this period was almost doubled
when there were isolated extra-cranial manifestations
[7]. It must be emphasized that GCA is a disease
with very heterogeneous signs and symptoms, mim-
icking many common conditions, and therefore physi-
cians should be familiar with this clinical variability
(see Table 1) to be able to raise their clinical suspicion.
In this regard, it is essential to educate and train primary
care physicians and specialists in Geriatrics and to
promote and facilitate communication pathways with
other specialists to allow earlier diagnosis [81].
Table 2 depicts some practical recommendations to
improve management, follow-up and prognosis.
Conclusions
GCA is an inflammatory disease with very heteroge-
neous and often nonspecific clinical manifestations that
can lead to serious and irreversible complications, being
visual loss, acute arterial ischemia and acute aortic
syndromes the most feared of them. This heterogen-
eity can lead to a low index of suspicion from attend-
ing physicians. It is crucial to establish an early
diagnosis and treatment to reduce the risk of develop-
ing such complications. It is also important to carry
out a close follow-up, since large vessel involvement
may occur years after initial recognition of the dis-
ease. Newer imaging techniques such as FDG-PET/
CT, MRI or CT-angiography can be an aid for diag-
nosis and also for follow-up of patients.
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Table 2 Practical recommendations and learning points in the
diagnostic approach and management of GCA
- Former term “temporal arteritis” might be misleading or confounding,
as virtually any large or medium-sized artery may be affected.
- GCA may present with isolated extra-cranial involvement.
- PMR may be present before, during or after diagnosis of GCA has
been established, and vice versa
- Comprehensive clinical assessment should include palpation of the
temporal arteries as well as palpation and auscultation of extracranial
vascular territories, including axillary and subclavian arteries, in order to
look for any one-sided vascular stenosis. Arterial pressures should also
be measured in all four limbs.
- Temporal artery biopsy is the gold standard for the diagnosis of GCA
with cranial manifestations. However, the temporal artery yield
decreases significantly in patients presenting with extra-cranial GCA.
- Temporal artery biopsy is positive in patients with cranial
manifestations even several weeks after the onset of glucocorticoids.
- When there is a very suggestive clinical picture and a positive imaging
test, presumptive diagnosis of GCA may be established, thus obviating
temporal artery biopsy.
- Glucocorticoid therapy should be started immediately in patients with
a high clinical suspicion of GCA, even before histologic confirmation or
imaging tests are available.
- When ophthalmologic symptoms are present, high doses of
glucocorticoids are recommended.
- After diagnosis of GCA has been established, it may be advisable to
use CT-angiography or FDG-PET/CT for screening of large-vessel
involvement.
- Large-vessel complications (aneurysm and dissection) may develop
several years after initial diagnosis of GCA, therefore long-term close
follow-up is advised.
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